CHEMOMAB THERAPEUTICS LTD. Up to [•] American Depositary Shares Or [•] Pre- funded Warrants to Purchase American Depositary Shares And [•] Warrants to Purchase American Depositary Shares UNDERWRITING AGREEMENTUnderwriting Agreement • March 21st, 2023 • Chemomab Therapeutics Ltd. • Pharmaceutical preparations
Chemomab Therapeutics Ltd., a company organized and existing under the laws of the State of Israel (the “Company”), proposes, subject to the terms and conditions contained herein, to sell to you and the other underwriters (the “Underwriters”) named on Schedule I to this Underwriting Agreement (this “Agreement”), for whom you are acting as Representative, if any (the “Representative”), an aggregate of (A) up to [•] (i) American Depositary Shares, or “ADS” (the “Firm Shares”), each representing 20 ordinary shares, no par value per share, of the Company (the “Ordinary Shares”) or (ii) [•] pre-funded warrants to purchase up to [•] ADSs at an exercise price of $0.01 per share, in the form attached hereto as Exhibit A (the “Pre-Funded Warrants”) and (B) [•] warrants, each warrant exercisable for one ADS at an exercise price of $[•] per ADS with a term of five years, in the form attached hereto as Exhibit B (the “Common Warrants” and together with the Pre-funded Warrants, the “Warrants”). The
